• Engel Ayer BotrelTobiasThttps://orcid.org/0000-0001-9137-0637CIOP - Centro Integrado de Oncologia e Pesquisa, Poços de Caldas, Brazil., Márcia Datz Abadi, Laura Chabrol Haas, Cássia Rita Pereira da Veiga, Dominihemberg de Vasconcelos Ferreira, and Denis Leonardo Jardim.
• CIOP - Centro Integrado de Oncologia e Pesquisa, Poços de Caldas, Brazil.
• J Med Econ. 2021 Jan 1; 24 (1): 291-298.

BackgroundConsidering clinical benefits of new combination therapies for metastatic renal-cell carcinoma (mRCC), this study aims to calculate the number needed to treat (NTT) and the cost of preventing an event (COPE) for pembrolizumab plus axitinib (P + A), and nivolumab plus ipilimumab (N + I) as first-line treatments, from the Brazilian private perspective.MethodsOverall survival (OS) and progression-free survival (PFS) data for intermediate- and poor-risk groups were obtained from KEYNOTE-426 and CHECKMATE-214 trials for P + A and N + I, respectively, versus sunitinib as mRCC first-line treatment.ResultsConsidering a 12-month time horizon, 6 patients should be treated with P + A to prevent one death with sunitinib use, resulting in a COPE of 3,773,865 BRL. Using N + I, NNT for 12-month OS rate was 13 compared to sunitinib, with a COPE of 6,357,965 BRL. Regarding PFS data, NNT was also 6 when comparing P + A versus sunitinib, with an estimated COPE of 3,773,865 BRL. Estimated NNT was 20 comparing N + I and sunitinib, resulting in a COPE of 10,172,744 BRL. Cost differences between two treatment options, reached more than 6 million BRL for PFS, and 2 million BRL for OS.ConclusionAt the 12-month landmark, P + A suggests better economic scenario versus N + I as first-line mRCC treatment option for intermediate- and poor-risk groups, through an indirect comparison using sunitinib as a common comparator.

57 keywords...

hide…